🚀 Apply for £10k+ grants with our Startup Launch Kit
shadow shadow shadow shadow shadow
    Country
    Opportunity Status
    Funding Instrument Type
    Category
    Clear

    Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)

    PAR-21-329

    National Institutes of Health

    Opening date 22 Sep 2021, 12:00AM

    Closing date 5 Nov 2024, 12:00AM

    Funding Opportunity Number: PAR-21-329

    Opportunity Category: Discretionary

    CFDA Number(s): 93.393 -- Cancer Cause and Prevention Research

    Cost Sharing or Matching Requirement: No

    Posted Date: Sep 22, 2021 12:00:00 AM EDT

    Closing Date: Nov 05, 2024 12:00:00 AM EST

    Award Ceiling: none

    Award Floor: none

    Eligible Applicants: Small businesses,Public and State controlled institutions of higher education,Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,State governments,Others (see text field entitled "Additional Information on Eligibility" for clarification),Private institutions of higher education,Public housing authorities/Indian housing authorities,Independent school districts,Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education,County governments,Native American tribal governments (Federally recognized),For profit organizations other than small businesses,Special district governments,City or township governments,Native American tribal organizations (other than Federally recognized tribal governments)

    Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

    Agency Name: National Institutes of Health

    Description: The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.

    Grantor Contact Information: NIH OER Webmaster OERWebmaster03@od.nih.gov

    We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.

    We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.

    • Required to run the website
    • Monitoring website usage and optimizing the user experience
    • Evaluation of marketing actions
    • Storage of your preferences from previous visits
    • Collecting user feedback to improve our website
    • Recording of your interests in order to provide customised content and offers
    Cookie Settings Accept